These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 232020)
21. Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats. Gonzalez Vera W; Fournié-Zaluski MC; Pham I; Laboulandine I; Roques BP; Michel JB J Pharmacol Exp Ther; 1995 Jan; 272(1):343-51. PubMed ID: 7815350 [TBL] [Abstract][Full Text] [Related]
22. A comparison of inhibition of angiotensin I conversion by three converting enzyme inhibitors in rats. Takata Y; Di Nicolantonio R; Hutchinson JS Clin Exp Pharmacol Physiol Suppl; 1982; 7():129-34. PubMed ID: 6183035 [TBL] [Abstract][Full Text] [Related]
23. A comparison of the activity of the angiotensin converting enzyme inhibitors SQ 14 225, SA 446, and MK 421. Takata Y; Di Nicolantonio R; Mendelsohn FA; Hutchinson JS; Doyle AE Clin Exp Pharmacol Physiol; 1983; 10(2):131-45. PubMed ID: 6307563 [No Abstract] [Full Text] [Related]
24. [Effects of 3 different angiotensin converting enzyme inhibitors, MK 421, SQ 14225 and SA 446 on renal function and blood pressure in patients with essential hypertension]. Tajima J; Abe K; Yasujima M; Tanno M; Yoshinaga K Nihon Jinzo Gakkai Shi; 1984 Jun; 26(6):779-89. PubMed ID: 6096607 [No Abstract] [Full Text] [Related]
25. Effect of enalapril (MK-421), an orally active angiotensin I converting enzyme inhibitor, on blood pressure, active and inactive plasma renin, urinary prostaglandin E2, and kallikrein excretion in conscious rats. Schiffrin EL; Gutkowska J; Thibault G; Genest J Can J Physiol Pharmacol; 1984 Jan; 62(1):116-23. PubMed ID: 6143602 [TBL] [Abstract][Full Text] [Related]
26. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Azizi M; Chatellier G; Guyene TT; Murieta-Geoffroy D; Ménard J Circulation; 1995 Aug; 92(4):825-34. PubMed ID: 7641363 [TBL] [Abstract][Full Text] [Related]
27. Antihypertensive action of a novel orally active angiotensin converting enzyme inhibitor altiopril calcium (MC-838) in several hypertensive models of rats: comparison with captopril. Aono J; Koga T; Yamazaki T; Shiraki Y; Sakai K Arch Int Pharmacodyn Ther; 1988; 292():203-22. PubMed ID: 3293542 [TBL] [Abstract][Full Text] [Related]
28. Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Iyer SN; Ferrario CM; Chappell MC Hypertension; 1998 Jan; 31(1 Pt 2):356-61. PubMed ID: 9453328 [TBL] [Abstract][Full Text] [Related]
29. Species difference of (2R,4R)-2-(o-hydroxyphenyl)-3-(3-mercaptopropionyl)-4-thiazolidinec arb oxylic acid (SA446) in inhibition of angiotensin converting enzyme. Nakata K; Iwatani T; Horiuchi M; Kito H; Yamauchi H; Iso T Jpn J Pharmacol; 1986 Mar; 40(3):367-72. PubMed ID: 3012163 [TBL] [Abstract][Full Text] [Related]
30. Potentiation of bradykinin effect by angiotensin-converting enzyme inhibition does not correlate with angiotensin-converting enzyme activity in the rat mesenteric arteries. Sivieri DO; Bispo-da-Silva LB; Oliveira EB; Resende AC; Salgado MC Hypertension; 2007 Jul; 50(1):110-5. PubMed ID: 17470724 [TBL] [Abstract][Full Text] [Related]
31. Effects of captopril and enalapril on sodium excretion and blood pressure in sodium-deficient dogs. McCaa RE; Gillespie JB Fed Proc; 1984 Apr; 43(5):1336-41. PubMed ID: 6323226 [TBL] [Abstract][Full Text] [Related]
32. Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme. Agata J; Ura N; Yoshida H; Shinshi Y; Sasaki H; Hyakkoku M; Taniguchi S; Shimamoto K Hypertens Res; 2006 Nov; 29(11):865-74. PubMed ID: 17345786 [TBL] [Abstract][Full Text] [Related]
33. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension. Pham I; Gonzalez W; el Amrani AI; Fournié-Zaluski MC; Philippe M; Laboulandine I; Roques BP; Michel JB J Pharmacol Exp Ther; 1993 Jun; 265(3):1339-47. PubMed ID: 8389863 [TBL] [Abstract][Full Text] [Related]
34. Responses of the renin-angiotensin system and kallikrein-kinin system to sodium and converting enzyme inhibitor (SQ 14,225). Matthews PG; Johnston CI Adv Exp Med Biol; 1979; 120B():447-57. PubMed ID: 390990 [TBL] [Abstract][Full Text] [Related]
36. Significance of kallikrein-kinin and renin-angiotensin systems in the hypotensive mechanism of angiotensin-I converting enzyme inhibitors in essential hypertensives. Iimura O; Shimamoto K Adv Exp Med Biol; 1989; 247A():39-48. PubMed ID: 2532450 [TBL] [Abstract][Full Text] [Related]
37. Angiotensin-converting enzyme inhibition, anti-hypertensive activity and hemodynamic profile of trandolapril (RU 44570). Brown NL; Badel MY; Benzoni F; Zanirato J; Vincent JC; Fichelle J; Worcel M Eur J Pharmacol; 1988 Mar; 148(1):79-91. PubMed ID: 3383998 [TBL] [Abstract][Full Text] [Related]
38. Renal excretion of an angiotensin I converting enzyme inhibitor (SA-446) in dogs. Abe Y; Okahara T; Miura K; Yukimura T; Takada T; Iwatani T; Iso T; Yamamoto K Naunyn Schmiedebergs Arch Pharmacol; 1984 Apr; 325(4):356-9. PubMed ID: 6328337 [TBL] [Abstract][Full Text] [Related]
39. Effect of SA-446, an angiotensin-converting enzyme inhibitor, on renal function in anesthetized dogs: special reference to arachidonic acid metabolites. Miura K; Yukimura T; Imanishi M; Okahara T; Abe Y; Yamamoto K J Cardiovasc Pharmacol; 1985; 7(1):102-7. PubMed ID: 2580127 [TBL] [Abstract][Full Text] [Related]
40. Inhibition of angiotensin-converting enzyme with quinapril (CI-906): investigation of antihypertensive mechanisms in spontaneously hypertensive rats. Säynävälammi P; Pörsti I; Nurmi AK; Seppälä E; Metsä-Ketelä T; Tuomisto L; Manninen V; Vapaatalo H J Pharmacol Exp Ther; 1986 Apr; 237(1):246-51. PubMed ID: 3007740 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]